Caris Life Sciences Proves its FDA-approved MI Cancer Seek® Announcement Caris Life Sciences, a global patient-oriented, promising AI techbio company, released a study in Oncotarget validating the clinical and analytical potential of MI Cancer Seek. This regulatory-approved assay is consi...
SpinaFX’s Device Received Approval as a Groundbreaking Device Designation by the US FDA Announcement The spinaFX Medical Inc., a known innovator in image-guided interventional spine care, has been positioned as a groundbreaking device designation for its main device, Triojection, by the ...
Ascentage’s Phase 3 Study of Lisaftoclax Announcement Ascentage Pharma, a leading marketizing level merger biopharmaceutical company involved in the development, exploration, and marketing of numerous different therapies to identify required medical needs in cancer, has received approval...
Valneva’s Chikungunya Vaccine Received Authorization in Canada Announcement Valneva SE, a specialized vaccine company, received marketing authorization from Health Canada for the single-dose vaccine IXCHIQ for serving prevention of disease related to the chikungunya virus for individual...
CIT and IFLI Partnered to Advance Cancer Therapies Announcement CIT Therapeutics Inc., a leading biotechnology company primarily aimed at accelerating next-generation small molecule therapeutics focusing on sumoylation for cancer treatment, has entered a partnership deal with the Institute for...
Vivani Medical Milestones and Update on Business Strategies, Released Financial Reports and Announced Equity Financing Business Updates Vivani Medical Inc., a leading biopharmaceutical company, updated its business plans. Vivani signed a share purchase agreement on 11 August 2025, to issue and...
Pilatus and Roche are Together in a Clinical Trial Collaboration Announcement Pilatus Biosciences Inc., a leading biopharmaceutical company leading in metabolic checkpoint immunotherapies for gastrointestinal and liver cancers entered into a clinical trial collaborative agreement with Roche. A...
Kodiak’s Business Status and Financial Reports Kodiak’s Recent Business Plans Kodiak Sciences Inc. showcased recent business highlights and financial results for the second quarter ending June 30, 2025. The tarcocimab phase 3 toplisted data is predicted to start in 1Q 2026 (6 month...
Siloam and AWS Cloud Entered a Partnership to Enhance Patient Care Announcement PT Siloam International Hospitals Tbk initially adopted cloud services involving initially from Amazon Web Services (AWS) to leverage AI-driven innovation and digital transformation in healthcare. With an almost n...
Medexus Wins this Quarter's Race with the Successful Debut of its New Drug Announcement Medexus Pharmaceuticals smartly achieved a modest revenue winner position in this quarter for its energized debut of its new drug GRAFAPEX. This new drug managed to recoup losses from generics eating into i...
